Current estimates
suggest that during
the first 10 years
of biosimilar availability, consumers could
save as much as $250 billion.
Current estimates
The Biosimilars Council
is a division of the Association for Accessible Medicines, formerly known as GPhA, who works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars.
Where should you get started?
The Council publishes a number of resources to promote knowledge around the advancement of biosimilars, but we would recommend starting with our Handbook – a complete resource on biosimilars in the United States.
Additionally, consider joining us at GRx+Biosims – an industry leading event that is focused on uniting the power of innovation, science, and policy to increase patient access to generic and biosimilar medicines.
What are biosimilars?
Put simply, biosimilars are biologic medicines that are highly similar to a corresponding brand biologic. Biosimilars offer a safe, effective, and affordable alternative for patients. They are approved by the U.S. Food and Drug Administration (FDA) and improve patient access to life-saving medicines.
Reports, videos, news sources, and more. Take some time to learn all about biosimilars and the benefits they offer US consumers.
Take a minute and learn all about biosimilars and our industry in an easy to digest format. The best part? It’s free.
We are always on the road advocating for biosimilars and invite you to join us. Check out the details for our next event and bring your friends.
